Latest by

Transgender People at High Risk for HIV, But Little Is Known About Prevention and Treatment

"There is probably no population that is both more heavily impacted [by HIV] and less discussed around the world than transgender people," said Susan Buchbinder, M.D., during a CROI 2016 presentation.

By Liz Highleyman for

NHPC 2015: Evidence for PrEP Efficacy Grows, but Implementation Presents Challenges

"We're now reaching a tipping point where clinicians are hearing that their colleagues are prescribing PrEP and maybe they could too," said Dawn Smith of the Centers for Disease Control and Prevention.

By Liz Highleyman for

Truvada PrEP Appears to Work for Transgender Women, but Only if Used Consistently

The more than 300 transgender women in the pivotal iPrEx pre-exposure prophylaxis (PrEP) trial had similar overall HIV infection rates whether they were randomized to take tenofovir/emtricitabine (Truvada) or placebo, but those with drug levels indic...

By Liz Highleyman for